Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
02 Agosto 2024 - 3:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number: 001-39950
Evaxion Biotech A/S
(Exact Name of Registrant as Specified in Its Charter)
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion
Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended
(File No. 333-266050), Form F-1 (File No. 333-276505), and Form F-1 (File No. 333-279153), including any prospectuses forming a part of
such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents
or reports subsequently filed or furnished.
Resignation of Jesper Nissen
On July 31, 2024, Jesper Nissen tendered his resignation as the Interim Chief Financial Officer
and Chief Operating Officer of Evaxion Biotech A/S (“Evaxion” or the “Company”), to be effective no earlier than
October 31, 2024. Mr. Nissen’s resignation was for personal reasons and was not a result of any disagreement with the Company on
any matter relating to the Company’s operations, policies or practices. The Company plans to initiate a search for a candidate to
assume Mr. Nissen’s responsibilities as the Chief Financial Officer.
The Company thanks Mr. Nissen for his invaluable service as its Chief Financial Officer over
the past year and as Chief Operating Officer over the past few years and wishes him well in his new endeavor.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Evaxion Biotech A/S |
|
|
Date: August 2, 2024 |
By: |
/s/ Christian Kanstrup |
|
|
Christian Kanstrup |
|
|
Chief Executive Officer |
|
|
|
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024